5.19
+0.03
(0.58%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 5.12 - 5.45 |
| 52 week | 1.57 - 5.45 |
| Open | 5.18 |
| Vol / Avg. | 10.21M/5.49M |
| Mkt cap | 1.51B |
| P/E | - |
| Div/yield | - |
| EPS | -0.83 |
| Shares | 290.88M |
| Beta | 1.26 |
| Inst. own | 18% |
Events
Aug 5, 2013
Q2 2013 MannKind Earnings Release
May 23, 2013
MannKind Annual Shareholder Meeting
- 1:00PM EDT -
May 15, 2013
MannKind at Bank of America Merrill Lynch Health Care Conference -
May 9, 2013
Q1 2013 MannKind Earnings Conference Call -
May 9, 2013
Q1 2013 MannKind Earnings Release
Mar 5, 2013
MannKind at Cowen Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | - | -483902.80% |
| Operating margin | - | -419885.70% |
| EBITD margin | - | -360165.70% |
| Return on average assets | -70.44% | -75.13% |
| Return on average equity | - | - |
| Employees | 246 | - |
| Carbon Disclosure Rating | - | - |
Address
28903 North Avenue Paine
VALENCIA, CA 91355
United States - Map
+1-661-7755300 (Phone)
+1-302-6365454 (Fax)
VALENCIA, CA 91355
United States - Map
+1-661-7755300 (Phone)
+1-302-6365454 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company�s product candidate, AFREZZA (insulin human) inhalation powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type I or type II diabetes for the control of hyperglycemia. The AFREZZA inhalation powder is centered on a class of potential of hydrogen (pH)-sensitive organic molecules. AFREZZA utilizes its Technosphere formulation technology. As of December 31, 2011, MannKind had not generated any product revenues. As of December 31, 2011, the AFREZZA clinical program had involved 61 different studies of AFREZZA and over 5,600 adult patients.
Officers and directors
| Alfred E. Mann | Chairman of the Board, Chief Executive Officer | |
| Hakan S. Edstrom | President, Chief Operating Officer, Director | |
| Matthew J. Pfeffer | Corporate Vice President and Chief Financial Officer | |
| Juergen A. Martens Ph.D. | Corporate Vice President - Technical Operations, Chief Technical Officer | |
| David B. Thomson Ph.D.,J.D. | Corporate Vice President, General Counsel and Corporate Secretary | |
| Diane M. Palumbo | Corporate Vice President - Human Resources | |
| Ronald Consiglio | Independent Director | |
| Michael A. Friedman M.D. | Independent Director | |
| Kent Kresa | Independent Director | |
| David H. MacCallum | Independent Director |